Anhui Huaheng Biotechnology Co., Ltd. (SHA:688639)
China · Delayed Price · Currency is CNY 34.30
-0.46 (-1.32%)
Feb 13, 2026, 3:00 PM CST
SHA:688639 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,459 | 1,805 | 1,704 | 1,220 | 841.86 | 466.43 |
Other Revenue | 372.99 | 372.99 | 234.23 | 198.65 | 112.23 | 20.82 |
| 2,832 | 2,178 | 1,938 | 1,419 | 954.1 | 487.24 | |
Revenue Growth (YoY) | 34.04% | 12.37% | 36.63% | 48.69% | 95.81% | -0.83% |
Cost of Revenue | 2,209 | 1,638 | 1,156 | 870.26 | 646 | 289.4 |
Gross Profit | 623.28 | 539.66 | 782.37 | 548.39 | 308.1 | 197.85 |
Selling, General & Admin | 261.66 | 221.48 | 172.08 | 142.22 | 79.93 | 42.76 |
Research & Development | 140.46 | 124.05 | 108.82 | 78.61 | 52.84 | 30.12 |
Other Operating Expenses | 1.22 | -13.41 | 4.55 | 7.97 | 6.58 | 6.32 |
Operating Expenses | 403.13 | 330.9 | 285.77 | 231.29 | 139.03 | 79.4 |
Operating Income | 220.15 | 208.75 | 496.6 | 317.1 | 169.06 | 118.45 |
Interest Expense | -51.66 | -37.87 | -10.64 | -0.54 | -1.11 | -2.83 |
Interest & Investment Income | 16.13 | 5.25 | 5.91 | 10.64 | 7.5 | 0.33 |
Currency Exchange Gain (Loss) | 14.04 | 14.04 | 7.06 | 5.43 | -0.16 | -4.37 |
Other Non Operating Income (Expenses) | -15.21 | -3.3 | -2.66 | -0.59 | -0.39 | -0.29 |
EBT Excluding Unusual Items | 183.46 | 186.87 | 496.27 | 332.04 | 174.91 | 111.3 |
Gain (Loss) on Sale of Investments | -1.62 | - | -0.31 | -0.75 | 1.06 | - |
Gain (Loss) on Sale of Assets | -0.35 | -0.37 | -2.67 | -4.62 | -0.36 | -0.3 |
Asset Writedown | -7.77 | - | - | - | -5.61 | - |
Other Unusual Items | 14.9 | 14.9 | 12.98 | 16.32 | 20.78 | 28.94 |
Pretax Income | 188.62 | 201.41 | 506.27 | 342.98 | 190.79 | 139.94 |
Income Tax Expense | 12.64 | 16.85 | 59.67 | 23.64 | 22.55 | 18.84 |
Earnings From Continuing Operations | 175.99 | 184.56 | 446.6 | 319.34 | 168.24 | 121.1 |
Minority Interest in Earnings | 11.26 | 4.96 | 2.46 | 0.69 | - | - |
Net Income | 187.25 | 189.52 | 449.06 | 320.03 | 168.24 | 121.1 |
Net Income to Common | 187.25 | 189.52 | 449.06 | 320.03 | 168.24 | 121.1 |
Net Income Growth | -37.38% | -57.80% | 40.32% | 90.23% | 38.92% | -4.18% |
Shares Outstanding (Basic) | 247 | 231 | 229 | 227 | 208 | 170 |
Shares Outstanding (Diluted) | 247 | 231 | 229 | 227 | 208 | 170 |
Shares Change (YoY) | 7.25% | 0.88% | 0.72% | 9.33% | 22.57% | -0.34% |
EPS (Basic) | 0.76 | 0.82 | 1.96 | 1.41 | 0.81 | 0.71 |
EPS (Diluted) | 0.76 | 0.82 | 1.96 | 1.41 | 0.81 | 0.71 |
EPS Growth | -41.61% | -58.16% | 39.31% | 73.99% | 13.35% | -3.85% |
Free Cash Flow | -482.07 | -723.72 | -967.75 | -98.92 | -84.93 | 36.93 |
Free Cash Flow Per Share | -1.96 | -3.13 | -4.22 | -0.43 | -0.41 | 0.22 |
Dividend Per Share | 0.250 | 0.250 | 0.621 | 0.428 | 0.262 | 0.160 |
Dividend Growth | -59.72% | -59.72% | 44.99% | 63.33% | 63.51% | - |
Gross Margin | 22.00% | 24.78% | 40.36% | 38.66% | 32.29% | 40.61% |
Operating Margin | 7.77% | 9.59% | 25.62% | 22.35% | 17.72% | 24.31% |
Profit Margin | 6.61% | 8.70% | 23.17% | 22.56% | 17.63% | 24.85% |
Free Cash Flow Margin | -17.02% | -33.23% | -49.93% | -6.97% | -8.90% | 7.58% |
EBITDA | 388.68 | 347.41 | 595.44 | 376.25 | 216.56 | 153.49 |
EBITDA Margin | 13.72% | 15.95% | 30.72% | 26.52% | 22.70% | 31.50% |
D&A For EBITDA | 168.52 | 138.66 | 98.84 | 59.15 | 47.5 | 35.04 |
EBIT | 220.15 | 208.75 | 496.6 | 317.1 | 169.06 | 118.45 |
EBIT Margin | 7.77% | 9.59% | 25.62% | 22.35% | 17.72% | 24.31% |
Effective Tax Rate | 6.70% | 8.37% | 11.79% | 6.89% | 11.82% | 13.46% |
Revenue as Reported | 2,832 | 2,178 | 1,938 | 1,419 | 954.1 | 487.24 |
Advertising Expenses | - | 4.84 | 3.33 | 1.33 | 0.7 | 0.37 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.